

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

ATTY. DOCKET NO.
MGH-028AUS

APPLICATION NO.
10/814,852

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Page 1 of 1

APPLICANT
Maurizio Fava, et al.

FILING DATE
March 31, 2004

GROUP
3626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE*
						RECEIVED
						SEP 29 2009
						OFFICE OF PETITIONS

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

/E.S./	Brown, Jr.; "The Crossover Experiment for Clinical Trials;" Publication of Stanford University Medical Center, Stanford, CA; Biometrics 36; March 1980; pages 69-79
/E.S./	Carriere; "Crossover Designs for Clinical Trials;" Statistics in Medicine; Vol. 13; April 1993; pages 1063-1069
/E.S./	Farlow et al.; "A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease;" European Neurology; Vol. 4, November 2000; pages 236-241
/E.S./	Hills et al.; "The Two-Period Cross-Over Clinical Trial;" British Journal of Clinical Pharmacology; July 1979; pages 7-20
/E.S./	Leber et al.; "Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection;" Elsevier Science Inc.; Controlled Clinical Trials; Vol. 19, Issue 2 April 1998; pages 178-187
/E.S./	Raskind et al.; "Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension;" American Academy of Neurology; June 2000; pages 2260-2269
/E.S./	Rosner et al.; "Randomized Discontinuation Design: Applied to Cytostatic Antineoplastic Agents;" Journal of Clinical Oncology; Vol. 20, No. 22; November 15, 2002; pages 4478-4484
/E.S./	Temple; "Special Study Designs: Early Escape, Enrichment, Studies in Non-Responders;" Communications in Statistics-Theory and Method; Vol. 23, Issue 2; 1994; pages 499-531
Examiner	/Eliza Squires/ Date Considered: 10/07/2009
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.